mRNA Pharmacology Optimization Platform
Creative Biolabs is devoted to offering mRNA pharmacology optimization services as a stand-alone service or part of a complete mRNA vaccine package for global customers. With years of experience, our professional scientists are happy to drive your research from any stage to the final manufacturing.
Creative Biolabs provides a range of technologies to improve the pharmacological aspects of mRNA, which includes 1) the stability of mRNA; 2) translation efficiency; 3) half-life; 4) efficient and correct protein production. The full services include:
Optimization Service of mRNA Translation and Stability
We use various mRNA modification approaches to help you improve stability and increase protein translation.
- Sequence and codon optimization.
- Synthetic cap analogs and capping enzymes. The efficient production of proteins from mRNA requires 5' cap structure.
- Regulatory sequences in the 5′ and 3′ UTR. The regulatory elements which are able to facilitate mRNA expression and extend half-life can be obtained from viral or eukaryotic genes.
- Poly(A) tail. Optimal length of poly(A) tail also profoundly influences the stability and translation of mRNA.
- Modified nucleosides. Modified nucleosides can reduce innate immune activation and increase translation.
- Separation and purification. Proper treatment (RNase III treatment and fast protein liquid chromatography) can reduce immune activation and increase translation.
Services of Immunogenicity Modulation
As an exogenous gene with immunostimulatory properties, mRNA may be beneficial or harmful for treatment. It is potentially beneficial for vaccination because it can provide adjuvant activity to drive dendritic cell (DC) maturation and thus elicit a strong sputum and B cell immune response. However, innate immune perception of mRNA expression is also associated with inhibition of antigen expression and may have a negative impact on the immune response. Based on these theories, Creative Biolabs provides following strategies to modulate immunogenicity.
- Appropriate purification of IVT mRNA
- Nucleosides modification
- FPLC (fast protein liquid chromatography)-purified
- Addition of adjuvant
Effective mRNA Delivery Service
Exogenous mRNA must penetrate the barrier of the lipid membrane to reach the cytoplasm for translation into a functional protein, therefore efficient in vivo mRNA delivery is critical to achieving therapeutic relevance. We offer two methodss for delivering mRNA vaccines.
- Loading mRNA into DCs ex vivo followed by re-infusion of the transfected cells.
- Direct parenteral injection of mRNA with or without a vector.
Fig.2 Major delivery methods for mRNA vaccines. (Pardi N. 2018)
For more detailed information, please feel free to contact us or directly send us an online inquiry.
Reference
- Pardi N, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018, 17(4):261-279.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
